InvestorsHub Logo
Followers 87
Posts 6641
Boards Moderated 1
Alias Born 09/18/2009

Re: DTGoody post# 42320

Monday, 04/15/2024 10:05:53 AM

Monday, April 15, 2024 10:05:53 AM

Post# of 42746
The only new filing I see from the four companies I track (Humanigen, Baudax, Novavax, and Sanofi), is from an upset an investment firm holding Novavax. The comments provided by the investment firm are legitimate, and actually reflect why I feel that Novavax really needs to use lenz as their vaccine enhancement, if the company is going to survive.

https://www.sec.gov/Archives/edgar/data/1000694/000139834424007144/fp0087987-1_ex992.htm

Recent studies indicate that Novavax has an advantage in booster antibody durability. That's a plus, especially as mRNA booster antibodies are degrading, and becoming less effective. And it is becoming evident that Serious Adverse Events are presenting after a third mRNA booster.

I hope that Humanigen and Novavax can partner, and take the majority of the US covid market, currently captured by Moderna.gov (US govt), and PfDA (Pfizer/BioNtech and their German govt and European bank ownership).